Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $11.59 and last traded at $11.59, with a volume of 189,004 shares changing hands. The stock had previously closed at $11.75.

Several research firms have commented on LXRX. ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. BidaskClub raised shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, June 14th. Zacks Investment Research cut shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 5th. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, August 1st. Finally, Wedbush reissued an “ourperform” rating and set a $39.00 target price on shares of Lexicon Pharmaceuticals in a research note on Monday, August 7th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $28.75.

The firm’s market cap is $1.22 billion. The stock has a 50-day moving average of $13.17 and a 200 day moving average of $14.91.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $18.34 million. Lexicon Pharmaceuticals had a negative return on equity of 94.87% and a negative net margin of 170.63%. Lexicon Pharmaceuticals’s revenue was down 40.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.37) EPS. Equities analysts expect that Lexicon Pharmaceuticals, Inc. will post ($1.47) earnings per share for the current fiscal year.

In other Lexicon Pharmaceuticals news, insider Lonnel Coats bought 30,000 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was acquired at an average cost of $12.54 per share, with a total value of $376,200.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.77% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of LXRX. State of Wisconsin Investment Board bought a new position in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $510,000. Highbridge Capital Management LLC bought a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $7,813,000. Pictet Asset Management Ltd. grew its stake in shares of Lexicon Pharmaceuticals by 10.4% during the 2nd quarter. Pictet Asset Management Ltd. now owns 67,950 shares of the biopharmaceutical company’s stock worth $941,000 after acquiring an additional 6,400 shares in the last quarter. First Mercantile Trust Co. grew its stake in shares of Lexicon Pharmaceuticals by 11.2% during the 2nd quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock worth $201,000 after acquiring an additional 1,227 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Lexicon Pharmaceuticals by 11.1% during the 1st quarter. Wellington Management Group LLP now owns 279,874 shares of the biopharmaceutical company’s stock worth $4,013,000 after acquiring an additional 27,964 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: “Lexicon Pharmaceuticals, Inc. (LXRX) Hits New 52-Week Low at $11.59” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/10/12/lexicon-pharmaceuticals-inc-lxrx-hits-new-52-week-low-at-11-59.html.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.